Jasper Therapeutics Inc
NASDAQ:JSPR
Intrinsic Value
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of JSPR.
Jasper Therapeutics Inc's market capitalization is 349.6m USD.
JSPR stock price is 23.21 USD.
JSPR.
JSPR. Open DCF Valuation
JSPR. Open Relative Valuation
JSPR has upside potential of 197% compared to the average analyst price target.
Open Wall St Estimates
JSPR has negative Free Cash Flow for the last twelve months.
JSPR has negative Operating Income for the last twelve months.
JSPR has negative Net Income for the last twelve months.
JSPR's ROE (Return on Equity) for the past 12 months is negative and is equal to -113%.
JSPR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 133%.
JSPR has negative three-year average ROE (Return on Equity): -83%. The company is not efficient at transforming stockholders' equity into net income.
JSPR has negative three-year average ROIC (Return on Invested Capital): -868%. The company is not efficient at using invested capital to generate operating income.
JSPR's short-term assets (89m USD) exceed its short-term liabilties (12m USD).
JSPR's long-term assets (95m USD) exceed its long-term liabilties (16m USD).
JSPR's D/E (Debt to Equity) is very low and is equal to 0.
JSPR's Altman Z-Score is very low and is equal to -0.69.
Fundamental Analysis
Jasper Therapeutics Inc
Balance Sheet Decomposition
Jasper Therapeutics Inc
| Current Assets | 88.9m |
| Cash & Short-Term Investments | 86.9m |
| Receivables | 250k |
| Other Current Assets | 1.8m |
| Non-Current Assets | 6m |
| PP&E | 4.2m |
| Other Non-Current Assets | 1.8m |
| Current Liabilities | 12.4m |
| Accounts Payable | 4.1m |
| Accrued Liabilities | 7.9m |
| Other Current Liabilities | 317k |
| Non-Current Liabilities | 4.1m |
| Other Non-Current Liabilities | 4.1m |
Earnings Waterfall
Jasper Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-68.9m
USD
|
|
Operating Income
|
-68.9m
USD
|
|
Other Expenses
|
4.4m
USD
|
|
Net Income
|
-64.5m
USD
|
Free Cash Flow Analysis
Jasper Therapeutics Inc
What is Free Cash Flow?
JSPR Profitability Score
Profitability Due Diligence
Jasper Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Jasper Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
JSPR Solvency Score
Solvency Due Diligence
Jasper Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Jasper Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JSPR Price Targets Summary
Jasper Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
JSPR
is 68.85 USD
with a low forecast of 55.55 USD and a high forecast of 84 USD.
Ownership
JSPR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
JSPR Price
Jasper Therapeutics Inc
| Average Annual Return | -27.81% |
| Standard Deviation of Annual Returns | 35.21% |
| Max Drawdown | -97% |
| Market Capitalization | 349.6m USD |
| Shares Outstanding | 15 063 900 |
| Percentage of Shares Shorted | 3.29% |
Company Profile
Jasper Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 25 full-time employees. The company went IPO on 2019-11-20. The firm has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. The company is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The firm also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.JSP191 clear hematopoietic stem cells from the bone marrow prior to transplant.
You don't have any saved screeners yet
